TREMFYA™ patient resources for your practice

Welcome to Janssen CarePath

We’re here to help with Janssen Medications

At Janssen CarePath, we’re committed to helping you get your patients started on the Janssen medications you prescribed, finding financial assistance options, and providing ongoing support to help them stay on prescribed Janssen therapy.

What Janssen CarePath can do for you on behalf of your patients

  • Conduct benefits investigations and provide insurance coverage information
  • Give you support with a dedicated Care Coordinator for you and your patients
  • Investigation of patient eligibility and coverage: requirements for prior authorization process and prior authorization support and status monitoring

What Janssen CarePath can do for your patients

  • Conduct insurance coverage review
  • Help identify financial assistance options for eligible patients
  • Provide care coordination with their specialty pharmacy or treatment provider
  • Provide patient support resources

TREMFYA™ is marketed by Janssen Biotech, Inc.


Get Your Office Started:


Indication

TREMFYA™ is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA™ is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA™ is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA™ after physician approval and proper training.

Important Safety Information For TREMFYA

Important Safety Information

Infections
TREMFYA™ may increase the risk of infection. Treatment with TREMFYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA™ until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA™. Initiate treatment of latent TB prior to administering TREMFYA™. Monitor patients for signs and symptoms of active TB during and after TREMFYA™ treatment. Do not administer TREMFYA™ to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA™.

Adverse Reactions
Most common (≥1%) adverse reactions associated with TREMFYA™ include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA™.  Provide the Medication Guide to your patients and encourage discussion.

067010-170208